Active Recombinant Human MSLN protein, Fc-tagged, FITC-Labeled

• Cat.No.: MSLN-0388H
• Product Overview: FITC-Labeled Recombinant Human MSLN protein(Glu296-Gly580), fused with Fc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: Fc
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Anti-Human MSLN MAb at 10 μg/mL (100 μL/well) can bind FITC-Labeled Human Mesothelin (296-580), Fc Tag with a linear range of 0.078-0.625 μg/mL (Ex.488 nm/Em.535 nm).
• Molecular Mass: This protein carries a human IgG1 Fc tag at the C-terminus.The protein has a calculated MW of 58.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Proteinlength: Glu296-Gly580
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: For long term, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after at:
  -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• Protein length: Glu296-Gly580

Gene Information

• Gene Name: MSLN mesothelin [ Homo sapiens ]
• Official Symbol: MSLN
• Synonyms: MSLN; mesothelin; CAK1; MPF; CAK1 antigen; megakaryocyte potentiating factor; soluble MPF mesothelin related protein; pre-pro-megakaryocyte-potentiating factor; SMRP
• Gene ID: 10232
• mRNA Refseq: NM_001177355
• Protein Refseq: NP_001170826
• MIM: 601051
• UniProt ID: Q13421

Reviews

05/22/2022

Very satisfied, great product.

03/06/2022

Product is high-quality.

09/30/2021

Excellent for experiments, reliable.

Q&As

What is the primary role of MSLN in normal tissues?

MSLN is normally expressed in mesothelial cells, playing a role in cell adhesion.

How is MSLN expression altered in cancerous cells?

In cancer, MSLN expression is significantly upregulated.

In which types of cancer is MSLN overexpressed?

MSLN is overexpressed in mesothelioma, ovarian, and pancreatic cancers.

Are there any therapeutic strategies targeting MSLN in cancer treatment?

Therapies targeting MSLN include antibody-drug conjugates and CAR-T cell therapies.

How can MSLN levels be detected and measured in clinical settings?

MSLN levels can be assessed through immunohistochemistry and serum biomarker tests.

What is the prognostic significance of MSLN overexpression in cancer patients?

MSLN overexpression is often associated with poor prognosis in cancer patients.

How does MSLN contribute to cancer progression and metastasis?

MSLN promotes tumor cell proliferation, invasion, and resistance to apoptosis.